-
1
المؤلفون: Keith T. Flaherty, Laure Moutouh-de Parseval, Michael D Pickard, Carmen Loquai, Victor Sandor, Naoya Yamazaki, Ivana Krajsová, Gabriella Liszkay, Reinhard Dummer, Dirk Schadendorf, Mario Mandalà, Ana Arance, Ralf Gutzmer, Claus Garbe, Paolo A. Ascierto, Helen Gogas, Caroline Robert, Jan Willem de Groot, Caroline Dutriaux, Vanna Chiarion Sileni
المساهمون: University of Zurich, Dummer, Reinhard
المصدر: The Lancet Oncology. 19:1315-1327
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Time Factors, Medizin, Phases of clinical research, Gene mutation, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Trametinib, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, Phenotype, Tolerability, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Progression-free survival, Protein Kinase Inhibitors, Aged, Performance status, business.industry, 030104 developmental biology, chemistry, Mutation, Benzimidazoles, Carbamates, business
وصف الملف: 775_Dummer_R._et_al._Overall_survival_in_patients_with_BRAF-mutant_melanoma_receiving_encorafenib_plus_Lancet_Oncol._2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb4f4dc2694f231c2c21cb1932e261Test
https://doi.org/10.1016/s1470-2045Test(18)30497-2 -
2
المؤلفون: Vanna Chiarion-Sileni, Ana Arance, Keith T. Flaherty, Ralf Gutzmer, Claus Garbe, Ivana Krajsová, Dirk Schadendorf, Naoya Yamazaki, Caroline Robert, Helen Gogas, Michael D Pickard, Caroline Dutriaux, Laure Moutouh-de Parseval, Jan Willem de Groot, Carmen Loquai, Paolo A. Ascierto, Victor Sandor, Mario Mandalà, Reinhard Dummer, Gabriella Liszkay
المصدر: The Lancet Oncology. 19:603-615
مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, medicine.medical_specialty, Skin Neoplasms, Time Factors, Phases of clinical research, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, Progression-free survival, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Sulfonamides, Performance status, business.industry, MEK inhibitor, Binimetinib, Middle Aged, medicine.disease, Progression-Free Survival, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Mutation, Benzimidazoles, Female, Carbamates, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b9a8d731aee37b91ba57a2467a28bbTest
https://doi.org/10.1016/s1470-2045Test(18)30142-6